StockData
Pure Bioscience, Inc. logo

Pure Bioscience, Inc. (PURE) stock

PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
Financials through Q4 FY2026, quarter ended Jul 31, 2026Last filing: 10-K on Oct 29, 2026Score 1/30
$0.07−0.01 (-12.10%)

Close on Oct 19, 2026Market cap $8.67MP/E –Yield –

Earnings

Pure Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Dec 14, 2026
Q1 FY2027 · estimated, during market hours
Revenue, Q3 FY2026
$506.00K
+3.1% on a year earlier
EPS, Q3 FY2026
-$0.01
-$0.01 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Pure Bioscience's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2027ended Oct 31, 2026Dec 14, 2026Expected––––
Q4 FY2026ended Jul 31, 2026Oct 29, 2026after the close–––Release
Q3 FY2026ended Apr 30, 2026Jun 15, 2026during market hours$506.00K+3.1%-$0.01Release
Q2 FY2026ended Jan 31, 2026Mar 17, 2026after the close$444.00K+13.6%-$0.01Release
Q1 FY2026ended Oct 31, 2025Dec 15, 2025during market hours$708.00K+27.3%$0.00Release
Q4 FY2025ended Jul 31, 2025Oct 29, 2025during market hours–––Release
Q3 FY2025ended Apr 30, 2025Jun 16, 2025during market hours$491.00K–-$0.01Release
Q2 FY2025ended Jan 31, 2025Mar 17, 2025during market hours$391.00K–-$0.01Release
Q1 FY2025ended Oct 31, 2024Dec 16, 2024during market hours$556.00K–-$0.01Release
Q4 FY2024ended Jul 31, 2024Oct 29, 2024during market hours–––Release
Q3 FY2024ended Apr 30, 2024Jun 14, 2024during market hours–––Release
Q2 FY2024ended Jan 31, 2024Mar 18, 2024during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Pure Bioscience has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Pure Bioscience puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Pure Bioscience filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?